Remote Buying of Abeona Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is readyRemote Selling of Abeona Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is ready- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
Omega Therapeutics (OMGA) – Investment Analysts’ Recent Ratings Changes via ETF Daily News
Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Recommendation of “Buy” by Brokerages via ETF Daily News
Nabriva Therapeutics plc (NASDAQ:NBRV) Expected to Post Quarterly Sales of $9.47 Million via ETF Daily News
$9.47 Million in Sales Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This Quarter via ETF Daily News
ProQR Therapeutics (NASDAQ:PRQR) Expected to Announce Quarterly Sales of $1.21 Million via ETF Daily News
Galectin Therapeutics (NASDAQ:GALT) Now Covered by StockNews.com via ETF Daily News
Indaptus Therapeutics (NASDAQ:INDP) Downgraded to “Hold” at Zacks Investment Research via ETF Daily News
Zacks Investment Research Downgrades Foghorn Therapeutics (NASDAQ:FHTX) to Sell via ETF Daily News
Frequency Therapeutics (NASDAQ:FREQ) Downgraded by Zacks Investment Research via ETF Daily News
Cardiol Therapeutics (NASDAQ:CRDL) Upgraded at Zacks Investment Research via ETF Daily News
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.
Analysis is available when the exchange & market are open.